VERAVera Therapeutics, Inc.

1. Sep 15, 2026Vera Therapeutics Announces TRUTAKNA ™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney.Regulation FD disclosure · press release
2. Aug 10, 2026Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results.Earnings release · press release
3. Jul 9, 2026On July 9, 2026, Vera Therapeutics, Inc. (the “Company”) announced that William Turner will no longer serve as the Company’s Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026.Director or officer change · Form 8-K
4. Jul 7, 2026On July 7, 2026, Vera Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted TRUTAKNA™ (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.Other event · Form 8-K
5. Jun 2, 2026On June 2, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support the potential full approval of atacicept in adults with IgA Nephropathy.Other event · Form 8-K
6. May 7, 2026Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results.Earnings release · press release
7. Mar 9, 2026On March 5, 2026, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christopher Hite to the Board, effective immediately.Director or officer change · Form 8-K
8. Feb 26, 2026Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results.Earnings release · press release
9. Dec 18, 2025On December 16, 2025, Vera Therapeutics, Inc. (the “Company”) announced that Jason Carter will no longer serve as the Company’s Chief Legal Officer, effective as of December 24, 2025.Director or officer change · Form 8-K
10. Dec 10, 2025Follow-On Public Offering On December 9, 2025, Vera Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named …Other event · Form 8-K
11. Nov 26, 2025On November 25, 2025, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed James R. Meyers to the Board, effective immediately.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.